Get started

Fdaapproval

CVS PHARMACY IS FILLING SCRIPTS FOR PALFORZIA - STRONG BUYWe just checked pharmacies around the North East PALFORZIA peanut allergy drug is available at CVS Pharmacy and is being filled at CVS Pharmacy CVS Pharmacy is currently the largest pharmacy chain in the United States by number of locations with over 9,600 pharmacies throughout the United States. Its parent company ranks as the 7th largest U.S. corporation by FY2017 revenues in the Fortune 500. The parent company of CVS Pharmacy's leading competitor (Walgreens) ranked 19th for the same time period. The stupid brokerage firms that just downgraded the stock price today because of a "so called slow roll-out" have no clue what they're doing or saying anymore. All these analysts had to do is pickup the phone and call around like we did! They're lazy!!! ANyone on this board wondering how easy it is to find out, call a CVS Pharmacy and ask them if they can fill a script for PALFORZIA, they will tell you YES,,, it is in the database for them to order..!!! We are passing along our research to some major brokerage firms so they will get behind the stock and push it up Palforzia Peanut Allergy Drug is available at CVS Pharmacy and soon to be available at Walgreens and other pharmacies throughout the USA This stock could blast off any day folks! We do not buy drug stocks so we are sitting on the sidelines just passing along solid and reliable information Factual information for this board is always a good thing to post especially since you don't get it from dumb analysts! DISCLAIMER This website and our posts are for general information only. No information, forward looking statements, or estimations presented herein represent any final determination on investment performance. While the information presented in this website and our posts has been researched and is thought to be reasonable and accurate, any investment is speculative in nature. StockKid, and/or our agents cannot and do not guarantee any rate of return or investment timeline based on the information presented herein. By reading and reviewing the information contained in this website and our posts, the user acknowledges and agrees that StockKid, and/or our agents do not assume and hereby disclaim any liability to any party for any loss or damage caused by the use of the information contained herein, or errors or omissions in the information contained in this website or our posts, to make any investment decision, whether such errors or omissions result from negligence, accident or any other cause. Investors are required to conduct their own investigations, analysis, due diligence, draw their own conclusions, and make their own decisions. Any areas concerning taxes or specific legal or technical questions should be referred to lawyers, accountants, consultants, brokers, or other professionals licensed, qualified or authorized to render such advice. In no event shall StockKid, and/or our agents be liable to any party for any direct, indirect, special, incidental, or consequential damages of any kind whatsoever arising out of the use of this website, our posts or any information contained herein. StockKid, and/or our agents specifically disclaim any guarantees, including, but not limited to, stated or implied potential profits, rates of return, or investment timelines discussed or referred to herein.
ALong
by UnknownUnicorn3159981
BXRX FDA approval lotto playThis idea comes from recent success in a Sprint trade. It was slow in coming, but it did come through very successfully, which is the impetus for this idea of "reading" tickers with binary events. This is purely a news driven idea in which there is no technical reading of the chart what-so-ever. I have no idea if this will be correct, and am really using this platform for journaling & finding others who use similar methods. I'm getting the tickers from a freely available online calendar with the PDUFA dates. I use a pendulum and cards I made up to gain information on the "energy" of the situation. Anyone doing anything similar, please contact me to share information. I'm definitely on the fringes here. BXRX has a deadline for an FDA approval tomorrow (2/20/20). My indications are that it is APPROVED. I don't read about the details of the application and I don't care, although reading it may help my insomnia ;) BXRX is currently trading at the LOD $7.88 - 5.97% Indications are it could go up to $9.14 The ATH is $9.60 We shall see...
BLong
by JenRz
5
LCI may start to climb after today's FDA approvalLannett stock has struggled lately due to opioid litigation and a weakening of its earnings forecast back in November. However, the company announced several product launches in December and early January, and today Lannett got FDA approval for, of all things, a cocaine-based anesthetic nasal spray. The stock has shown little positive reaction to any of this news, but that might change if analysts start to adjust their earnings forecasts to reflect the new product offerings. Despite its underwhelming reaction to the news today, I think Lannett may start to show momentum this week as investors digest the announcement from today. Lannett has an attractive forward P/E of 6.84 and a history of beating analyst expectations on its earnings reports. Its last round of guidance was neutral, with increased administrative and sales costs offset by decreased tax burden and interest expense. Lannett should have enough cash on hand to cover its product launches thanks to a convertible notes offering last year. It has about $100 million in cash per its last earnings report, although with apparently $66 million in debt due toward the end of this year.
LLong
by ChristopherCarrollSmith
$KDMN Set To Keep Climbing$KDMN is set up well both technically and fundamentally. The FDA just approved CLOVIQUE (TM), A Room-Temperature Stable Trientine Hydrochloride Product. This bodes well for the company as it moves forward. According to the press release: Product Offers Room Temperature Stability, Improving Convenience for Patients NEW YORK, NY / ACCESSWIRE / October 21, 2019 / Kadmon Holdings, Inc. (KDMN) today announced that the U.S. Food and Drug Administration (FDA) has approved CLOVIQUE™ (Trientine Hydrochloride Capsules, USP), a room-temperature stable, branded generic product. Trientine hydrochloride is used for the treatment of Wilson's disease in patients who are intolerant of penicillamine. CLOVIQUE is the first FDA-approved trientine product in a portable blister pack that offers room temperature stability for up to 30 days, potentially providing patients more convenience. In a recently published survey, approximately 30% of Wilson's disease patients cited product storage as a medication-associated inconvenience of disease management.1 "CLOVIQUE is an innovative treatment option that can be stored at room temperature, which is an added convenience for Wilson's disease patients," said Harlan W. Waksal, M.D., President and CEO of Kadmon. "We are pleased to offer CLOVIQUE to patients in need as part of our goal to develop novel therapies for chronic, rare diseases." Kadmon has immediately commenced commercialization activities for CLOVIQUE through Kadmon Pharmaceuticals, its wholly-owned commercial operation. In September 2019, the FDA approved Kadmon's generic Trientine Hydrochloride Capsules USP, 250 mg, available in 100-count bottles. The FDA had determined Kadmon's Trientine Hydrochloride Capsules to be bioequivalent and therapeutically equivalent to the reference listed drug, Syprine® Capsules, 250 mg. About Wilson's Disease Wilson's disease is a rare genetic disorder causing excess copper accumulation in the body that results in neurological and metabolic adverse events. About Kadmon Kadmon is a biopharmaceutical company developing innovative products for significant unmet medical needs. Our product pipeline is focused on inflammatory and fibrotic diseases as well as immuno-oncology. As always, use protective stops and trade with caution. Good luck to all!
KLong
by OptionsGains